Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

The purpose of this study was to investigate the antitumor activity of regorafenib and sorafenib in preclinical models of HCC and to assess their mechanism of action by associated changes in protein expression in a HCC-PDX mouse model. Both drugs were administered orally once daily at 10 mg/kg (rego...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Kissel, Maria, Berndt, Sandra, Fiebig, Lukas, Kling, Simon, Ji, Qunsheng, Gu, Qingyang, Lang, Tina, Hafner, Frank-Thorsten, Teufel, Michael, Zopf, Dieter
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739799/
https://ncbi.nlm.nih.gov/pubmed/29291014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22334
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы